Among the 2,488 patients who underwent the proteomic test from 2011 to 2013, 257 (10%) of those tested had no lung biopsy or tumor tissue available for EGFR testing, which illustrates the capacity for liquid biopsy tests to improve access to lung cancer molecular testing. The gene discussed is EGFR; the disease is lung carcinoma.